SCHEMBL17808919

SCHEMBL17808919

CCCc1cnc2c(O)c(-c3c(C)noc3C)ccn2c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 4/20 0.34
▸ USP2 O75604 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CYP1A2 P05177 3/20 0.33
▸ BRD4 O60885 7/20 0.33
▸ NR3C1 P04150 1/20 0.33
▸ ERN1 O75460 1/20 0.33
▸ FFAR1 O14842 2/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ADRA2B P18089 3/20 0.32
▸ FTO Q9C0B1 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ ADRA2A P08913 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ ADRA1A P35348 1/20 0.32
▸ EED O75530 1/20 0.32
▸ SUZ12 Q15022 1/20 0.32
▸ EZH2 Q15910 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17808737 0.82 NR3C1 (0.34) BRD4NR3C1ERN1FFAR1FTO
SCHEMBL17808921 0.81 USP1 (0.37) CYP3A4CYP2C19CYP1A2BRD4NR3C1
SCHEMBL17808730 0.80 PRKCQ (0.34) USP2ALOX15HSD17B10
SCHEMBL10027311 0.79 MAPT (0.36) HSD17B10ALDH1A1
SCHEMBL17808764 0.78 PDE3B (0.36) —
SCHEMBL17808843 0.78 TP53 (0.43) NR3C1HSD17B10ADRA2BALDH1A1ADRA2A
SCHEMBL17808740 0.77 USP7 (0.36) CYP3A4USP2TSHRCYP2C19CYP1A2
SCHEMBL19361118 0.77 AURKA (0.36) HSD17B10
SCHEMBL17808760 0.76 LMNA (0.36) CYP3A4USP2TSHRCYP2C19CYP1A2
SCHEMBL17808723 0.76 CYP3A4 (0.38) CYP3A4CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2021-07-29 — — US disclosed
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2021-05-18 — — US disclosed
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2020-10-08 — — US disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2019-05-14 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
WO-2016086261-A1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CYP3A4 122/4885USP2 4626/4885TSHR 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback